Shares of Cingulate Inc. (NASDAQ:CING – Get Free Report) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $4.81 and traded as high as $5.48. Cingulate shares last traded at $5.11, with a volume of 950,497 shares traded.
Analysts Set New Price Targets
CING has been the topic of a number of research reports. Roth Capital set a $9.00 price objective on Cingulate and gave the stock a “buy” rating in a research note on Sunday, August 23rd. Wall Street Zen lowered shares of Cingulate from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings downgraded shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cingulate presently has an average rating of “Moderate Buy” and an average target price of $27.00.
Check Out Our Latest Stock Analysis on Cingulate
Cingulate Stock Performance
The company has a market capitalization of $76.45 million, a P/E ratio of -1.84 and a beta of -0.88. The firm’s fifty day moving average is $4.81 and its 200 day moving average is $5.38.
Cingulate (NASDAQ:CING – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). On average, analysts forecast that Cingulate Inc. will post -2.19 EPS for the current year.
Hedge Funds Weigh In On Cingulate
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC raised its stake in Cingulate by 14.8% in the first quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock valued at $869,000 after buying an additional 18,000 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in Cingulate in the first quarter valued at approximately $116,000. Renaissance Technologies LLC acquired a new position in Cingulate in the 1st quarter worth approximately $198,000. Finally, BlackRock Inc. acquired a new stake in Cingulate during the 2nd quarter valued at approximately $291,000. Hedge funds and other institutional investors own 41.31% of the company’s stock.
Cingulate Company Profile
Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day. Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD. The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates.
See Also
- Five stocks we like better than Cingulate
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
